Skip to main content
. Author manuscript; available in PMC: 2022 Jun 4.
Published in final edited form as: Nat Aging. 2021 Dec 6;1(12):1148–1161. doi: 10.1038/s43587-021-00143-2

Fig. 4. Transcriptomic alterations in skeletal muscle with young serum treatment are predominated by EVs.

Fig. 4.

a, Schematic of the experimental paradigm for RNAseq analyses after serum injections. b, Linear Discriminant Analysis (LDA) of RNA-seq data acquired from injured aged skeletal muscles receiving sham, young serum, or EV-depleted young serum injections. c, Venn diagram displaying overlap of global differentially expressed (DE) genes when comparing young serum vs. sham and EV-depleted young serum vs. sham (Log fold change magnitude 0.1, false discovery rate magnitude 0.1). d, Gene ontology (GO) terms for highly differentially expressed due to the presence of EVs in young serum (log fold change magnitude higher than 1.5, false discovery rate magnitude lesser than 0.1).